(Q39232996)

English

Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial

scientific article published on 30 January 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

0 references

chronic obstructive pulmonary disease

0 references

1 reference

based on heuristic

author name string

Jin-Ping Zheng

1

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Fu-Qiang Wen

2

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Chun-Xue Bai

3

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Huan-Ying Wan

4

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Jian Kang

5

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Ping Chen

6

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Wan-Zhen Yao

7

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Li-Jun Ma

8

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Xia Li

9

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Luca Raiteri

10

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Marco Sardina

11

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Yi Gao

12

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Bai-Song Wang

13

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Nan-Shan Zhong

14

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

PANTHEON study group

15

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

publication date

30 January 2014

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

The Lancet. Respiratory medicine

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

187-194

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of preventing exacerbations on deterioration of health status in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The burden of COPD in The Netherlands: results from the Confronting COPD survey.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

N-acetyl cysteine protects osteoblastic function from oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

COPD exacerbations: definitions and classifications.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Characteristics and outcomes of chronic obstructive pulmonary disease in never smokers in Denmark: a prospective population study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Respiratory syncytial virus inhibits ciliagenesis in differentiated normal human bronchial epithelial cells: effectiveness of N-acetylcysteine

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970286-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-2600(13)70286-8

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39232996&oldid=1813917209"